United Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
United Therapeutics has a total shareholder equity of $6.1B and total debt of $400.0M, which brings its debt-to-equity ratio to 6.6%. Its total assets and total liabilities are $7.1B and $1.0B respectively. United Therapeutics's EBIT is $1.3B making its interest coverage ratio -8.9. It has cash and short-term investments of $3.3B.
Key information
6.6%
Debt to equity ratio
US$400.00m
Debt
| Interest coverage ratio | -8.9x |
| Cash | US$3.33b |
| Equity | US$6.10b |
| Total liabilities | US$1.02b |
| Total assets | US$7.12b |
Recent financial health updates
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04Financial Position Analysis
Short Term Liabilities: UTHR's short term assets ($4.0B) exceed its short term liabilities ($873.4M).
Long Term Liabilities: UTHR's short term assets ($4.0B) exceed its long term liabilities ($148.8M).
Debt to Equity History and Analysis
Debt Level: UTHR has more cash than its total debt.
Reducing Debt: UTHR's debt to equity ratio has reduced from 36.8% to 6.6% over the past 5 years.
Debt Coverage: UTHR's debt is well covered by operating cash flow (284.2%).
Interest Coverage: UTHR earns more interest than it pays, so coverage of interest payments is not a concern.